We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

114 hedge funds and large institutions have $353M invested in C4 Therapeutics in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

614% more call options, than puts

Call options by funds: $257K | Put options by funds: $36K

52% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 31

19% more capital invested

Capital invested by funds: $298M → $353M (+$55.1M)

1.5% more ownership

Funds ownership: 80.81% → 82.31% (+1.5%)

6% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 16

1% more funds holding

Funds holding: 113 → 114 (+1)

Holders
114
Holders Change
+1
Holders Change %
+0.88%
% of All Funds
1.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
47
Reduced
31
Closed
16
Calls
$257K
Puts
$36K
Net Calls
+$221K
Net Calls Change
-$2.03M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$12.9M
2
SCM
Soleus Capital Management
Connecticut
+$12M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$8.18M
4
Goldman Sachs
Goldman Sachs
New York
+$3M
5
WA
Wasatch Advisors
Utah
+$2.78M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$14.7M
2
ACH
ArrowMark Colorado Holdings
Colorado
-$7.79M
3
SFM
Sphera Funds Management
Israel
-$5.32M
4
Millennium Management
Millennium Management
New York
-$3.21M
5
RI
RTW Investments
New York
-$2.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$1.72M -$1.43M -138,132 -41%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.33M +$190K +18,332 +14%
Bank of America
28
Bank of America
North Carolina
$1.22M +$806K +77,676 +126%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$1.14M +$533K +51,294 +65%
Citadel Advisors
30
Citadel Advisors
Florida
$1.14M +$1.06M +101,836 +364%
Mariner
31
Mariner
Kansas
$1.1M -$1.82K -175 -0.1%
Rafferty Asset Management
32
Rafferty Asset Management
New York
$988K +$1.17M +112,650 New
State of Wisconsin Investment Board
33
State of Wisconsin Investment Board
Wisconsin
$978K +$58.4K +5,627 +5%
Walleye Capital
34
Walleye Capital
New York
$970K -$2.11M -203,656 -65%
Voloridge Investment Management
35
Voloridge Investment Management
Florida
$943K -$1.62M -156,362 -59%
Citigroup
36
Citigroup
New York
$913K +$1.03M +99,385 +2,115%
AQR Capital Management
37
AQR Capital Management
Connecticut
$808K +$181K +17,439 +23%
CSS
38
Cubist Systematic Strategies
Connecticut
$753K -$367K -35,310 -29%
VIG
39
Vienna Insurance Group
Poland
$745K – – –
Swiss National Bank
40
Swiss National Bank
Switzerland
$705K – – –
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$702K -$71.7K -6,902 -8%
Barclays
42
Barclays
United Kingdom
$660K +$740K +71,244 +1,783%
Wellington Management Group
43
Wellington Management Group
Massachusetts
$593K +$702K +67,604 New
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$562K +$41.3K +3,981 +7%
RJA
45
Raymond James & Associates
Florida
$556K +$357K +34,390 +118%
Renaissance Technologies
46
Renaissance Technologies
New York
$551K +$533K +51,300 +446%
Fidelity Investments
47
Fidelity Investments
Massachusetts
$504K +$584K +56,210 +4,291%
HF
48
HRT Financial
New York
$500K -$401K -38,653 -40%
M&T Bank
49
M&T Bank
New York
$448K -$113K -10,844 -17%
AllianceBernstein
50
AllianceBernstein
Tennessee
$418K -$32.2K -3,100 -6%
1
2
3 4 5

CCCC Hedge Fund Activity: Q3 2022 in Review

114 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q3 2022, worth a combined $353M — up 19% from $298M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CCCC positions and 16 closed out — a net gain of 1 holder — while 47 added to existing stakes and 31 trimmed.

The largest buyer was State Street, adding an estimated $12.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $14.7M.

  • 114 institutional investors held C4 Therapeutics (CCCC) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $353M of C4 Therapeutics stock for Q3 2022, up 19% quarter-over-quarter.
  • 17 funds opened new C4 Therapeutics positions in Q3 2022 and 16 closed out, a net change of +1 holder.
  • The largest C4 Therapeutics buyer in Q3 2022 was State Street, an estimated $12.9M added.
  • The largest C4 Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $14.7M sold.

Based on aggregated 13F filings for Q3 2022.